.png)
Key Players Driving the Malaria Vaccine Market: GSK vs. Serum Institute of India
The Malaria Vaccine Market is currently defined by two major players and their respective vaccines, creating a dynamic competitive landscape. GlaxoSmithKline (GSK) developed and launched the first-ever WHO-recommended malaria vaccine, RTS,S/AS01, brand-named Mosquirix. Its successful pilot programs demonstrated the feasibility and impact of a malaria vaccine in real-world settings, paving the way for a broader rollout. GSK's vaccine laid the foundation for the entire market by proving that a malaria vaccine could be a vital public health tool.
The market has since welcomed a new, highly promising competitor: the R21/Matrix-M vaccine, developed by the University of Oxford and manufactured by the Serum Institute of India (SII). The R21 vaccine is notable for its higher reported efficacy in trials and its potential for more cost-effective, large-scale production. This new entrant promises to address the long-standing issue of supply constraints, as SII has the capacity to produce a massive volume of doses. The introduction of the R21 vaccine is set to reshape the Malaria Vaccine Market by increasing competition, lowering prices, and ultimately, reaching a much larger population.
FAQs
Q: Who makes the RTS,S (Mosquirix) vaccine?A: The RTS,S vaccine was developed by GlaxoSmithKline (GSK) in partnership with the PATH Malaria Vaccine Initiative.
Q: What is the significance of the R21 vaccine?A: The R21 vaccine, manufactured by the Serum Institute of India, is the second WHO-approved malaria vaccine and is notable for its higher reported efficacy and large-scale, low-cost production capacity.